Navigation Links
Study Reinforces Safety of Long-term Biologic Treatment for Rheumatoid Arthritis

A new study has emphasised the safety and efficacy of Enbrel (etanercept) in the long-term treatment of rheumatoid arthritis (RA) patients .

Biologics, such as etanercept, work by blocking the action of a naturally occurring protein in the body called tumour necrosis factor that is involved in causing inflammation. When combined with methotrexate, etanercept, also known as an anti-TNF therapy, etanercept has shown to halt radiographic damage in patients with moderate RA activity over multiple years, which means the disease is halted at that stage.

The study was conducted by a team of researchers at Wyeth Pharmaceuticals.

As part of the study, researchers analysed 2,054 patients receiving this biologic treatment for up to nine years by monitoring them for serious adverse events (SAEs), serious and opportunistic infections, sepsis, malignancies and lymphomas.

Researchers found that the overall rates of SAEs were similar to control groups (0.11 pt-yr and 0.17 pt/yr vs 0.11-0.20/pt yr), as were serious infections, and reports of opportunistic infection were rare, that means that there were improvements in disability whilst safety was also sustained over the long-term in the patients.

The study adds to the clinical evidence highlighting the role of prevention of disease progression through earlier anti-TNF treatment. Given the significant social and economical burden of this disease this makes good sense for patients and healthcare systems alike.

Enbrel has a well-characterized safety profile and is well tolerated. Although a rare event, a higher than expected rate of lymphoma was observed in the analysis. However, further study is required to establish whether this is related to TNF antagonist exposure or reflects the elevated risk of lymphoma in patients with RA.

These strong data should give doctors the confidence to consider a biologic earlier in patients with aggressi ve and progressive rheumatoid arthritis, and patients should now have the prospect of less disability with a treatment which has also proven to have a good long-term safety, Professor Lars Klareskog of Karolinska Institute Karolinska University Sweden, said.

Professor Emilio Martin Mola of the Rheumatology Unit at Hospital Universitario La Paz, Spain added: With both earlier and continuous use of Enbrel we can prevent the debilitating affects of RA taking hold and maintain this response for many years. Its critical that appropriate funding for biologics is sourced to continue the fight against serious inflammatory diseases, such as RA.

The findings of the study were presented at the EULAR (European League Against Rheumatism) congress.


'"/>




Related medicine news :

1. Tomato Sauce reduces Cancer Risk- Study
2. Study on obesity and heart failure
3. National Lung Study in the process
4. Study casts doubt on keyboard ills
5. Study reveals how stress can make you sick
6. Study reveals how stress can make you sick
7. Study supports vegetable diet
8. Study to look at early surgery to treat epilepsy
9. Its Never Too Late to Stop Smoking,Study Finds
10. New Technique to Study Infants Brain.
11. Groundbreaking Study Gives Hope For Patients With Kidney Cancer
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/7/2016)... ... February 07, 2016 , ... Dr. ... Kybella® to his medical and surgical expertise. Technically known as deoxycholic acid or ... used as a non-surgical alternative for reduction of fat below the chin (aka ...
(Date:2/6/2016)... , ... February 06, 2016 , ... Shark Finds ... announce the launch of a new DRTV campaign with Belly Bands. , Having a ... everything from sprays to puppy pads and find nothing works, get Belly Bands, ...
(Date:2/5/2016)... (PRWEB) , ... February 05, 2016 , ... ... the availability of the company's lighter, sleeker next generation LYNX VR Indoor Trainer ... , Improvements in design and manufacturing not only reduce the weight of ...
(Date:2/5/2016)... , ... February 05, 2016 , ... ... domestic franchisees of Popeyes Louisiana Kitchen restaurants, launched the 14th annual “Appetite for ... kids and adults with muscular dystrophy, ALS and related diseases that severely limit ...
(Date:2/5/2016)... (PRWEB) , ... February 05, 2016 , ... After years ... General Hospital Burn Unit, plastic and cosmetic surgeon Dr. Wayne Carman transitioned to chief ... Hospital. He successfully completed his first three-year term as chief and began a second ...
Breaking Medicine News(10 mins):
(Date:2/5/2016)... , Feb. 5, 2016  As people age, it ... multitude of recommended screenings and tests that are linked ... priority. However, for the majority of aging individuals, hearing ... planning. For the 37.5 million American adults who report ... present to make hearing health a 2016 healthy aging ...
(Date:2/5/2016)... , Feb. 5, 2016  Aralez Pharmaceuticals Inc. ... of POZEN Inc. ("POZEN") and Tribute Pharmaceuticals Canada Inc. ("Tribute") ... and shareholders of Tribute. The combined company will operate ... company with operations in Canada , ... United States . Under the terms of the ...
(Date:2/5/2016)... , Feb. 5, 2016 Aethlon Medical, Inc. (Nasdaq: ... Chairman and CEO, will be presenting at Source Capital Group,s ... York, NY at 2:15 p.m. ET on Wednesday, ... Immunotherapy Panel discussion taking place at 3:15 p.m. ET. ... approximately one hour after the conclusion of the live event. ...
Breaking Medicine Technology: